Oxaliplatin (OX) after irinotecan (IRI): antitumour activity and clinical benefit of 3rd and higher line chemotherapy with ox for patients (pts) with metastatic colorectal cancer (MCC) after failure of IRIAlbrecht Kretzschmar, Peter Reichardt, Peter Thuss‐Patience et al.|European Journal of Cancer|1999Cited by 4